| Literature DB >> 35528007 |
Lin Qi1, Ya-Ping Liu1, Shi-Ming Wang1, Hao Shi1, Xiao-Li Chen1, Ning-Ning Wang1, Ying-Chun Su1.
Abstract
Objective: To investigate the effect of BMI in male and/or female partners on embryo development and clinical pregnancy outcome during ART.Entities:
Keywords: BMI; abortion rate; clinical pregnancy rate; high-quality embryo rate; live birth rate
Mesh:
Year: 2022 PMID: 35528007 PMCID: PMC9068983 DOI: 10.3389/fendo.2022.856667
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1(A) Flow charts representing the populations included in the current study. (B) Pie charts representing the percentages of different groups.
Baseline data of female and male in different groups.
| Item | Group A (Female and Male BMI < 24 kg/m2, N=2,526) | Group B (Female BMI < 24 kg/m2 and Male BMI≥ kg/m2, N=4,349) | Group C (Female BMI ≥ 24 kg/m2 and Male BMI< kg/m2, N=1,455) | Group D (Female and Male BMI ≥ kg/m2, N=2,800) | P value |
|---|---|---|---|---|---|
| Female | |||||
| Age (year) | 30.55±4.60 | 31.61±4.81 | 30.77±5.04 | 32.00±5.13 | <0.01 |
| Basal FSH (mIU/mL) | 7.09±2.53 | 7.11±2.70 | 6.51±2.18 | 6.65±2.36 | <0.030 |
| Basal LH (mIU/mL) | 5.86±4.23 | 5.83±4.62 | 5.93±4.79 | 5.50±4.82 | 0.027β |
| Basal AMH (mIU/mL) | 3.53±2.80 | 3.32±2.70 | 3.92±3.26 | 3.64±3.12 | <0.05 |
| AFC | 14.14±6.39 | 13.47±6.52 | 15.57±7.07 | 14.84±7.26 | <0.010 |
| No. of oocytes retrieved | 12.89±5.74 | 12.36±5.80 | 13.26±6.18 | 12.79±6.28 | <0.02
|
| No. of MII oocytes | 10.61±5.02 | 10.18±5.02 | 10.87±5.31 | 10.53±5.42 | <0.02 |
| Male | |||||
| Age (year) | 31.32±5.38 | 32.56±5.61 | 31.42±5.37 | 32.82±5.67 | 0.000 |
| Semen volume (ml) | 3.07±1.35 | 3.01±1.23 | 3.02±1.26 | 3.00±1.33 | <0.010 |
| Concentration (106/ml) | 46.24±34.05 | 45.35±36.34 | 46.44±34.68 | 45.15 ±35.02 | >0.05 |
| PR (%) | 32.65±13.27 | 31.75±14.01 | 32.49±12.93 | 31.85±13.32 | <0.05 |
| NP (%) | 9.11±3.92 | 9.41±3.78 | 9.32±4.07 | 9.37±3.65 | <0.010 |
| IM (%) | 51.89±18.52 | 53.21±17.45 | 52.61±16.95 | 53.25±16.54 | <0.010 |
| DFI (%) | 13.60±7.37 | 16.44±10.71 | 13.58±7.46 | 17.42±11.47 | 0.000 |
BMI, Body mass index; FSH, follicle stimulating hormone; LH, luteinizing Hormone; AMH, Anti-Müllerian hormone; AFC, Antral Follicle Count; PR, Progressive motility; NP, Non-progressive motility; IM, In-motility; DFI, Sperm DNA fragmentation index. P < 0.05 was considered to be statistically significant.
Group A vs Group B.
Group A vs Group C.
Group A vs Group D.
αGroup B vs Group C.
βGroup B vs Group D.
γGroup C vs Group D.
Etiological classification and methods of assisting pregnancy in different groups.
| Item | Group A (Female and Male BMI < 24 kg/m2, N=2,526) | Group B (Female BMI < 24 kg/m2 and Male BMI≥ kg/m2, N=4,349) | Group C (Female BMI ≥ 24 kg/m2 and Male BMI< 24 kg/m2, N=1,455) | Group D (Female and Male BMI ≥ 24 kg/m2, N=2,800) | P value |
|---|---|---|---|---|---|
| Etiology | 0.000abcαβγ | ||||
| Tubal factors | 49.47%(1249/2525) | 46.65% (2029/4349) | 43.64% (635/1455) | 42.82% (1199/2800) | |
| Endometriosis | 6.22% (157/2525) | 6.62% (288/4349) | 4.26% (62/1455) | 4.21% (118/2800) | |
| PCOS | 6.50% (164/2525) | 6.25% (272/4349) | 15.60% (227/1455) | 14.50% (406/2800) | |
| Ovarian disease | 3.72% (94/2525) | 4.48% (195/4349) | 4.12% (60/1455) | 5.39% (151/2800) | |
| For unknown reasons | 25.11% (634/2525) | 28.01% (1218/4349) | 24.95% (363/1455) | 25.14% (704/2800) | |
| Male factors | 8.99% (227/2525) | 7.98% (347/4349) | 7.42% (108/1455) | 7.96% (223/2800) | |
| Method of ART | 0.368abcαβγ | ||||
| IVF | 79.49% (2007/2525) | 80.01% (3483/4349) | 81.03% (1179/1455) | 81.25% (2275/2800) | |
| ICSI | 20.51% (518/2525) | 19.91% (866/4349) | 18.97% (276/1455) | 18.75% (526/2800) | |
BMI, Body mass index; PCOS, Polycystic ovary syndrome; ART, assisted reproduction technology; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection. P < 0.05 was considered to be statistically significant.
Group A vs Group B.
Group A vs Group C.
Group A vs Group D.
αGroup B vs Group C.
βGroup B vs Group D.
γGroup C vs Group D.
Male factors include oligozoospermia, asthenospermia, teratozoospermia, dysspermia, and chromosome and single gene genetic disorders, and so on.
Effect of female or (and) male BMI on oocytes maturation, fertilization, embryo development, and embryo quality in IVF cycles.
| Item | Group I (Female and Male BMI < 24 kg/m22, N=2,007) | Group II (Female BMI < 24 kg/m2 and Male BMI≥ 24 kg/m2, N=3,483) | Group III (Female BMI ≥ 24 kg/m2 and Male BMI< 24 kg/m2, N=1,179) | Group IV (Female and Male BMI ≥ kg/m2, N=2,275) | P value |
|---|---|---|---|---|---|
| Mature oocyte rate (%) | 0.82±0.15 | 0.83±0.15 | 0.83±0.15 | 0.83±0.16 | >0.05 |
| 2PN fertilization rate (%) | 0.65±0.18 | 0.66±0.19 | 0.64±0.18 | 0.65±0.19 | 0.006α
|
| Normal fertilization cleavage rate (%) | 0.99±0.05 | 0.99±0.05 | 0.99±0.04 | 0.99±0.05 | >0.05 |
| High quality embryo rate (%) | 0.71±0.25 | 0.70±0.25 | 0.71±0.27 | 0.72±0.25 | >0.05 |
| Blastocyst formation rate (%) | 0.52±0.33 | 0.51±0.34 | 0.52±0.32 | 0.51±0.33 | >0.05 |
| High scoring blastocyst rate (%) | 0.29±0.32 | 0.28±0.32 | 0.27±0.30 | 0.28±0.32 | >0.05 |
BMI, Body Mass Index; 2PN, two Pronuclear; P < 0.05 was considered to be statistically significant.
Group I vs Group II.
Group I vs Group III.
Group I vs Group IV.
αGroup II vs Group III.
βGroup II vs Group IV.
γGroup III vs Group IV.
Effect of female and Male BMI on oocytes maturation, fertilization, embryo development, and embryo quality in ICSI cycles.
| Item | Group i (Female and Male BMI < 24 kg/m2, N=519) | Group ii (Female BMI < 24 kg/m2 and Male BMI ≥ 24 kg/m2, N=866) | Group iii (Female BMI ≥ 24 kg/m2 and Male BMI < 24 kg/m2, N=276) | Group iv (Female and Male BMI ≥ 24 kg/m2, N=525) | P value |
|---|---|---|---|---|---|
| Mature oocyte rate (%) | 0.85±0.14 | 0.84±0.14 | 0.84±0.14 | 0.84±0.14 | >0.05 |
| 2PN fertilization rate (%) | 0.75±0.18 | 0.75±0.18 | 0.74±0.21 | 0.75±0.19 | >0.05 |
| Normal fertilization cleavage rate (%) | 0.98±0.06 | 0.99±0.05 | 0.99±0.04 | 0.99±0.05 | >0.05 |
| High quality embryo rate (% | 0.69±0.25 | 0.69±0.25 | 0.64±0.28 | 0.62±0.22 | 0.02 |
| Blastocyst formation rate (%) | 0.47±0.32 | 0.50±0.33 | 0.50±0.33 | 0.49±0.33 | >0.05 |
| High scoring blastocyst rate (%) | 0.24±0.30 | 0.26±0.31 | 0.26±0.31 | 0.28±0.31 | >0.05 |
BMI, Body Mass Index; 2PN, two Pronuclear; P < 0.05 was considered to be statistically significant.
Group i vs Group ii.
Group i vs Group iii.
Group i vs Group iv.
αGroup ii vs Group iii.
βGroup ii vs Group iv.
γGroup iii vs Group iv.
Effect of female and Male BMI on pregnancy outcome in IVF cycles.
| Item | Group I (Female and Male BMI < 24 kg/m22, N=2,007) | Group II (Female BMI < 24 kg/m2 and Male BMI ≥ 24 kg/m2, N=3,483) | Group III (Female BMI ≥ 24 kg/m2 and Male BMI < 24 kg/m2, N=1,179) | Group IV (Female and Male BMI ≥ kg/m2, N=2,275) | P value |
|---|---|---|---|---|---|
| CRP (%) | 62.13% (1247/2007) | 60.24% (2098/3483) | 64.03% (755/1179) | 59.12% (1345/2275) | 0.045 |
| AR (%) | 13.95% (174/1247) | 15.82% (332/2098) | 15.63% (118/755) | 20.00% (269/1345) | 0.000 |
| LBR (%) | 53.46% (1073/2007) | 50.70% (1766/3483) | 54.03% (637/1179) | 47.25% (1075/2275) | 0.000 |
BMI, Body Mass Index; CPR, clinical pregnancy rate; AR, abortion rate; LBR, live birth rate, P < 0.05 was considered to be statistically significant.
Group I vs Group II.
Group I vs Group III.
Group I vs Group IV.
αGroup II vs Group III.
βGroup II vs Group IV.
γGroup III vs Group IV.
Effect of female and Male BMI on pregnancy outcome in ICSI cycles.
| Item | Group i (Female and Male BMI < 24 kg/m2, N=519) | Group ii (Female BMI < 24 kg/m2 and Male BMI ≥ 24 kg/m2, N=866) | Group iii (Female BMI ≥ 24 kg/m2 and Male BMI < 24 kg/m2, N=276) | Group iv (Female and Male BMI ≥ 24 kg/m2, N=525) | P value |
|---|---|---|---|---|---|
| CRP (%) | 68.40% (357/519) | 59.12% (512/866) | 68.12% (188/276) | 60.38% (317/525) | 0.000 |
| AR (%) | 8.68% (31/357) | 11.72% (60/512) | 19.15% (36/188) | 14.83% (47/317) | 0.001 |
| LBR (%) | 62.62% (325/519) | 52.19% (452/866) | 55.07% (152/276) | 51.62% (271/525) | 0.000 |
BMI, Body Mass Index; CPR, clinical pregnancy rate; AR, abortion rate; LBR, live birth rate, P < 0.05 was considered to be statistically significant.
Group i vs Group ii.
Group i vs Group iii.
Group i vs Group iv.
αGroup ii vs Group iii.
βGroup ii vs Group iv.
γGroup iii vs Group iv.
Logistic regression analysis on the effect of female and male BMI on pregnancy outcomes in IVF cycles.
| Item | Group I (Female and Male BMI < 24 kg/m2) | Group II (Female BMI < 24 kg/m2 and Male BMI ≥ 24 kg/m2) | P value | Group III (Female BMI ≥ 24 kg/m2 and Male BMI < 24 kg/m2) | P value | Group IV (Female and Male BMI ≥ 24 kg/m2) | P value |
|---|---|---|---|---|---|---|---|
| CPR | |||||||
| OR (95% CI) | Reference | 0.92 (0.83-1.03) | 0.165 | 1.09 (0.94-1.26) | 0.283 | 0.88 (0.78-1.00) |
|
| aOR (95% CI) | Reference | 1.01 (0.88-1.16) | 0.894 | 1.12 (0.93-1.35) | 0.233 | 0.97 (0.83-1.13) | 0.671 |
| AR | |||||||
| OR (95% CI) | Reference | 1.16 (0.95-1.41) | 0.144 | 1.14 (0.89-1.47) | 0.303 | 1.15 (1.25-1.90) |
|
| aOR (95% CI) | Reference | 1.08 (0.88-1.32) | 0.477 | 1.18 (0.91-1.53) | 0.214 | 1.46 (1.17-1.81) |
|
| LBR | |||||||
| OR (95% CI) | Reference | 0.90 (0.80-0.99) |
| 1.023 (0.89-1.18) | 0.757 | 0.78 (0.69-0.88) |
|
| aOR (95% CI) | Reference | 1.01 (0.90-1.14) | 0.840 | 0.97 (0.84-1.13) | 0.721 | 0.86 (0.75-0.97) |
|
CPR, clinical pregnancy rate; AR, abortion rate; LBR, live birth rate; OR, Ratio ratio; aOR, Adjusted Ratio ratio; bold values means P < 0.05 was considered to be statistically significant.
Logistic regression analysis on the effect of female and male BMI on pregnancy outcomes in ICSI cycles.
| Item | Group i (Female and Male BMI < 24 kg/m2) | Group ii (Female BMI < 24 kg/m2 and Male BMI ≥ 24 kg/m2) | P value | Group iii (Female BMI ≥ 24 kg/m2 and Male BMI < 24 kg/m2) | P value | Group iv (Female and Male BMI ≥ 24 kg/m2) | P value |
|---|---|---|---|---|---|---|---|
| CPR | |||||||
| OR (95% CI) | Reference | 0.66 (0.52-0.83) |
| 0.97 (0.71-1.33) | 0.860 | 0.70 (0.54-0.90) |
|
| aOR (95% CI) | Reference | 0.73 (0.58-0.93) |
| 1.03 (0.74-1.44) | 0.868 | 0.79 (0.60-1.04) | 0.097 |
| AR | |||||||
| OR (95% CI) | Reference | 1.39 (0.88-2.20) | 0.156 | 2.48 (1.48-4.17) |
| 1.82 (1.12-2.94) |
|
| aOR (95% CI) | Reference | 1.25 (0.78-1.99) | 0.360 | 2.23 (1.30-3.83) |
| 1.32 (0.79-2.20) | 0.268 |
| LBR | |||||||
| OR (95% CI) | Reference | 0.65 (0.52-0.81) |
| 0.73 (0.54-0.98) |
| 0.63 (0.49-0.81) |
|
| aOR (95% CI) | Reference | 0.72 (0.57-0.91) |
| 0.76 (0.55-1.04) | 0.087 | 0.74 (0.57-0.96) |
|
CPR, clinical pregnancy rate; AR, abortion rate; LBR, live birth rate; OR, Ratio ratio; aOR, Adjusted Ratio ratio; bold values means P < 0.05 was considered to be statistically significant.